The Proactive Molecular Risk Classifier for Endometrial cancers (ProMisE) is demonstrated to be a low-cost and simple tool, broadly available in clinical practice, to easily determine the patients risk subgroup; it is based on three key components: IHC for MMR proteins, sequencing for the presence of POLE EDMs and IHC for p53 [52]. The gene discussed is MRC1; the disease is endometrial cancer.